Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anamarija M Perry

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|April 23, 2013
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 casesAnamarija M Perry, David Crockett, Bhavana J Dave, et al.
Haematologica|January 12, 2023
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphomaJoo Y Song, Mary Nwangwu, Ting-Fang He, et al.
Blood|September 7, 2013
Indolent T-cell lymphoproliferative disease of the gastrointestinal tractAnamarija M Perry, Roger A Warnke, Qinglong Hu, et al.
British Journal of Haematology|November 17, 2024
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasmsEmily O Symes, Peng Wang, Payal Sojitra, et al.
Hematological Oncology|October 21, 2015
Non-Hodgkin lymphoma in Romania: a single-centre experienceBogdan Fetica, Patriciu Achimas-Cadariu, Bogdan Pop, et al.
Leukemia & Lymphoma|April 2, 2015
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcomeGabriel C Caponetti, Bhavana J Dave, Anamarija M Perry, et al.
British Journal of Haematology|February 11, 2014
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximabAnamarija M Perry, Yuridia Alvarado-Bernal, Javier A Laurini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOPJoo Y Song, Anamarija M Perry, Alex F Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Human Pathology|August 6, 2014
BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphomaSamantha L Kendrick, Lucas Redd, Andrea Muranyi, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|April 23, 2013
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 casesAnamarija M Perry, David Crockett, Bhavana J Dave, et al.
Haematologica|January 12, 2023
Low T-cell proportion in the tumor microenvironment is associated with immune escape and poor survival in diffuse large B-cell lymphomaJoo Y Song, Mary Nwangwu, Ting-Fang He, et al.
Blood|September 7, 2013
Indolent T-cell lymphoproliferative disease of the gastrointestinal tractAnamarija M Perry, Roger A Warnke, Qinglong Hu, et al.
British Journal of Haematology|November 17, 2024
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasmsEmily O Symes, Peng Wang, Payal Sojitra, et al.
Hematological Oncology|October 21, 2015
Non-Hodgkin lymphoma in Romania: a single-centre experienceBogdan Fetica, Patriciu Achimas-Cadariu, Bogdan Pop, et al.
Leukemia & Lymphoma|April 2, 2015
Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcomeGabriel C Caponetti, Bhavana J Dave, Anamarija M Perry, et al.
British Journal of Haematology|February 11, 2014
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximabAnamarija M Perry, Yuridia Alvarado-Bernal, Javier A Laurini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOPJoo Y Song, Anamarija M Perry, Alex F Herrera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Human Pathology|August 6, 2014
BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphomaSamantha L Kendrick, Lucas Redd, Andrea Muranyi, et al.
Pageof 6